With pivotal sepofarsen data due, the group will hope to get one up on Editas.
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
The FDA scrambles for more rapid Covid-19 tests, and the device sector enjoys a late flurry of deals.
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.